{
  "nctId": "NCT03051620",
  "briefTitle": "Predictive Value of Bone Turnover Markers During Discontinuation With Alendronate",
  "officialTitle": "Predictive Value of Bone Turnover Markers During Discontinuation With Alendronate",
  "protocolDocument": {
    "nctId": "NCT03051620",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2018-04-23",
    "uploadDate": "2020-11-26T06:42",
    "size": 311074,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT03051620/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [],
  "studyType": "OBSERVATIONAL",
  "enrollmentInfo": {
    "enrollmentCount": 142,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2017-02-01",
    "completionDate": "2019-01-31",
    "primaryCompletionDate": "2019-01-31",
    "firstSubmitDate": "2017-02-07",
    "firstPostDate": "2017-02-14"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Postmenopausal women (postmenopausal for at least two years)\n* Men above 50 years\n* Treatment for at least five years with alendronate\n* BMD T-score total hip \\> -2.5\n* BMD T-score lumbar spine (L1-L4) \\> -4\n\nExclusion Criteria:\n\n* Any low-energy fracture within the previous five years during alendronate treatment (not including fingers, toes, or skull)\n* Low-energy vertebral fracture at any time\n* Low-energy hip fracture at any time\n* Ongoing treatment with glucocorticoids\n* Metabolic bone disease\n* Hormone replacement therapy\n* Cancer\n* Other conditions affecting bone metabolism",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "50 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "If Carboxy-terminal Collagen Crosslinks (CTX) Three and Six Months After Stopping Alendronate Predicted TH BMD (Total Hip BMD) Loss Above the Least Significant Change at Month 12 at the Individual Level.",
        "description": "We constructed receiver operating characteristic (ROC) curves to evaluate if carboxy-terminal collagen crosslinks (CTX) three and six months after stopping alendronate predicted TH BMD loss above the least significant change (LSC) at month 12 at the individual level.",
        "timeFrame": "Baseline and one year after baseline"
      }
    ],
    "secondary": [
      {
        "measure": "Percent Change in Bone Turnover Markers Measured Three and Six Months After Stopping Alendronate Treatment and BMD After One and Two Years",
        "description": "We constructed receiver operating characteristic (ROC) curves to evaluate if changes in p-CTX or p-PINP measured three and six months after stopping alendronate predicted TH BMD loss above the least significant change at month 12 and/or month 24 at the individual level.",
        "timeFrame": "one and two years after baseline"
      },
      {
        "measure": "Number of Participants in Which CTX Increased Above the Least Significant Change",
        "description": "Number of participants in which CTX increased above the least significant change.\n\nThe Department of Clinical Biochemistry, Rigshospitalet, Glostrup, Denmark provided the the least significant change for p-CTX \\> 30%.",
        "timeFrame": "From baseline to month 24"
      },
      {
        "measure": "The Number of Participants Who Lost BMD Beyond the Least Significant Change (LSC) at the Lumbar Spine and Total Hip.",
        "description": "the number of patients who lost BMD beyond the LSC at the lumbar spine (\\>3%) and total hip (\\>5%)",
        "timeFrame": "from baseline to month 24"
      },
      {
        "measure": "If Baseline Bone Turnover Markers at the Time of Alendronate Discontinuation Predict Changes in BMD After One and Two Years.",
        "description": "We constructed receiver operating characteristic (ROC) curves to evaluate if baseline p-CTX or baseline p-PINP at the time of alendronate discontinuation predicted TH BMD loss above the least significant change at month 12 and/or month 24 at the individual level.",
        "timeFrame": "Changes in TH BMD after one and two years."
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 4,
      "otherCount": 0,
      "totalCount": 5
    },
    "studyDesign": {
      "phases": [],
      "isRandomized": false,
      "isMasked": true
    },
    "overallComplexityScore": 49,
    "complexityCategory": "Moderate"
  },
  "collectionDate": "2025-09-22T02:30:04.223Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}